IFNB1 and rheumatoid arthritis: If increased osteoclastogenesis is confirmed in patients with either no detectable T1IFN or IFNβ/α > 1.3 in comparison to detectable but IFNβ/α ≤ 1.3, abatacept (which is already FDA-approved for treatment of RA) may be a more ideal than a TNFi as initial biologic therapy in this subset of patients.